An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...

Among 91 women, those who used a closed-loop insulin delivery system spent an average of 65.4% of time in pregnancy-specific ...

According to Mordor Intelligence, the global clinical trials market is valued at USD 90.1 billion in 2025 and is projected to surpass USD 123.5 billion in 2030, growing at a 6.51% CAGR during the ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ...

Oct 6 (Reuters) - Eli Lilly (LLY.N), opens new tab will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, ...

Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, ...

Oct 7 (Reuters) - Peter Marks, the former top vaccine regulator who was ousted from the U.S. Food and Drug Administration earlier this year, has joined Eli Lilly (LLY.N), opens new tab, the drugmaker ...

A Delaware federal judge dismissed a lawsuit brought by Eli Lilly, the maker of the blockbuster weight loss drugs Mounjaro and Zepbound, against a telehealth company it accused of “deceptive” ...

Despite the company's run in recent years, it's not too late to buy. Even with headwinds it has encountered this year, the drugmaker is arguably one of the top stocks in its industry to buy right now.